CymaBay Therapeutics, Inc. (0I5P.L) LSE
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
CymaBay Therapeutics, Inc.
Address
7575 Gateway Boulevard
Newark, CA 94560
United States of America (the)
Phone
510 293 8800
Website
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
101
First IPO Date
January 29, 2018
Key Executives
| Name | Title | Pay | Year Born |
| Sujal A. Shah | President, Chief Executive Officer & Director | 1.04M | 1973 |
| Klara A. Dickinson-Eason | Chief Regulatory & Quality Assurance Officer | 441,836 | 1968 |
| Paul T. Quinlan | General Counsel, Chief Compliance Officer & Corporate Secretary | 629,720 | 1963 |
| Charles A. McWherter | President of Research & Development and Chief Scientific Officer | 700,648 | 1955 |
| Ben Kozub | Head of Commercial | 0 | N/A |
| Harish Shantharam | Chief Financial Officer, Principal Accounting & Financial Officer | 0 | 1982 |
| Ken Boehm | Senior Vice President of Human Resources | 0 | N/A |
| Patrick J. O'Mara | Senior Vice President of Business Development | 0 | 1961 |
| Becki Filice | 130494Senior Vice President of Portfolio & Product Leadership | 0 | 1961 |
| Robert L. Martin | Senior Vice President of Manufacturing & Nonclinical Development | 0 | 1962 |
Description
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on creating and providing treatments for liver and various other chronic conditions. Its leading investigational drug is seladelpar (MBX-8025), a selective agonist for the peroxisome proliferator activated receptor delta, which is presently in a Phase III clinical trial for primary biliary cholangitis (PBC). This compound has also successfully completed a Phase 2b clinical study for patients suffering from nonalcoholic steatohepatitis (NASH). The company is also developing MBX-2982, currently in a Phase 2a clinical study to address hypoglycemia in individuals with type 1 diabetes. CymaBay has a licensing arrangement with ABW Cyclops SPV LP to support the development of seladelpar for PBC. Moreover, it holds a worldwide license from Janssen Pharmaceuticals, Inc., enabling it to research, develop, and commercialize agents targeting an undisclosed metabolic disease. Founded in 1988 and originally known as Metabolex, Inc., CymaBay Therapeutics, Inc. is headquartered in Newark, California.
